Phosphorus-32 microparticles for locally advanced pancreatic cancer: how and when?

Luca Urso,Luca Filippi

DOI: https://doi.org/10.1080/17434440.2024.2352009

IF: 3.439

2024-05-07

Expert Review of Medical Devices

Abstract:KEYWORDS: Pancreatic ductal adenocarcinoma (PDAC) stands as the sixth leading cause of global mortality and the fourth in Europe. The mortality rates exhibit an upward trajectory, marked by significant variations among different countries [ Citation 1 ]. These differences may be attributed to a range of factors, including distinct genetic and cultural backgrounds, as well as unequal access to emerging therapeutic options. While surgery remains the sole curative option, approximately 30% of patients at diagnosis face inoperability due to locally advanced disease. Despite notable advances in recent years, the prognosis in locally advanced PDAC remains grim, with a median overall survival spanning 9–11 months [ Citation 2 ]. While there is a broad consensus that patients with inoperable PDAC should undergo chemotherapy, the therapeutic approach in this clinical context remains suboptimal. Indeed, current chemotherapeutic regimens predominantly rely on data extrapolated from trials involving metastatic patients, including chemotherapy alone or chemotherapy followed by radiotherapy [ Citation 3 ]. In this context, an unmet need for alternative therapeutic options is undeniable. Internal radiation therapy (IRT) is a well-established approach in nuclear medicine that involves the insertion of radioactive implants directly into cancerous tissue [ Citation 4 , Citation 5 ]. Along this trajectory, a recently introduced medical device utilizes silicon microparticles containing radioactive phosphorus ( 32 P), implanted via endoscopic ultrasound (EUS), for treating locally advanced PDAC [ Citation 6 ]. Our objective is to provide a concise overview of the methodology ('how') and the most effective timing ('when') for the application of 32 P-microparticles within the therapeutic framework for locally advanced PDAC, through a comprehensive review of the existing scientific evidence ().

engineering, biomedical